title: [Atypical metastatic breast localization in lung cancer].
abstract: BACKGROUND
  In the context of bronchial cancers, the most frequent sites for metastases to occur are the lung, bone, brain, liver and adrenal glands. However, metastasis to other sites does additionally occur and this might be influenced by the biological characteristics of the tumour.
  
  
  METHODS
  We report the case of a 54-year-old woman with a primary bronchial adenocarcinoma with an EML4-ALK translocation. During her treatment with crizotinib, the patient developed a lesion in her right breast. The initial pathological diagnosis was of an invasive ductal adenocarcinoma of the breast. However, an additional immuno-histochemical analysis revealed it to be a metastasis from her bronchial tumour.
  
  
  CONCLUSIONS
  This case is an illustration that, in the context of a lung cancer with ALK rearrangement, synchronous or secondary lesions must be interpreted with caution. Specific biological analysis - ALK immunohistochemistry or FISH - must be performed to confirm a primary or metastatic origin for these lesions.
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix Marseille université, 13920 Marseille cedex 15, France.
authors.forename: A
authors.initials: A
authors.lastname: Serraille
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix Marseille université, 13920 Marseille cedex 15, France.
authors.forename: H
authors.initials: H
authors.lastname: Barazzutti
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix Marseille université, 13920 Marseille cedex 15, France; Inserm U911, centre de recherche en oncologie biologique et oncopharmacologie, faculté de médecine, Aix Marseille université, 13005 Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Greillier
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix Marseille université, 13920 Marseille cedex 15, France; Inserm U911, centre de recherche en oncologie biologique et oncopharmacologie, faculté de médecine, Aix Marseille université, 13005 Marseille, France. Electronic address: fabrice.barlesi@ap-hm.fr.
authors.forename: F
authors.initials: F
authors.lastname: Barlesi
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology*; D000077192:Adenocarcinoma of Lung; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000556:secondary*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis / Q000235:genetics / Q000556:secondary*; D020732:Cytogenetic Analysis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology*; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D014178:Translocation, Genetic
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion
keywords: ALK rearrangement; Cancer bronchique; Lung cancer; Réarrangement ALK; Sites métastatiques atypiques; Unusual metastatic pattern